Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulsatile Afatinib in Recurrent or Progressive Brain Cancer
NCT02423525Phase 1Completed
- Sponsor
- Santosh Kesari
- Start
- Dec 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of afatinib in brain cancer, sponsored by Santosh Kesari. Primary endpoints: Rate of dose limiting toxicities at 28 days and Maximum Tolerated Dose at 28 days. Started Dec 2016; status: completed.
02
Drugs
afatinib
03
Conditions
brain cancer
Beyond the preview
Go deeper on NCT02423525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423525.